- Home
- JUNS vs LSB Comparison
JUNS vs LSB Comparison
Compare JUNS & LSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JUNS
- LSB
- Stock Information
- Founded
- JUNS 2015
- LSB 2002
- Country
- JUNS United States
- LSB China
- Employees
- JUNS N/A
- LSB N/A
- Industry
- JUNS
- LSB
- Sector
- JUNS
- LSB
- Exchange
- JUNS NYSE
- LSB NYSE
- Market Cap
- JUNS 20.5M
- LSB 22.3M
- IPO Year
- JUNS 2024
- LSB N/A
- Fundamental
- Price
- JUNS $1.11
- LSB $0.98
- Analyst Decision
- JUNS
- LSB
- Analyst Count
- JUNS 0
- LSB 0
- Target Price
- JUNS N/A
- LSB N/A
- AVG Volume (30 Days)
- JUNS 723.0K
- LSB 19.7K
- Earning Date
- JUNS 08-11-2025
- LSB 08-14-2025
- Dividend Yield
- JUNS N/A
- LSB N/A
- EPS Growth
- JUNS N/A
- LSB N/A
- EPS
- JUNS N/A
- LSB N/A
- Revenue
- JUNS N/A
- LSB $79,415,311.00
- Revenue This Year
- JUNS N/A
- LSB $39.33
- Revenue Next Year
- JUNS N/A
- LSB $75.61
- P/E Ratio
- JUNS N/A
- LSB N/A
- Revenue Growth
- JUNS N/A
- LSB N/A
- 52 Week Low
- JUNS $0.51
- LSB $0.36
- 52 Week High
- JUNS $19.51
- LSB $6.82
- Technical
- Relative Strength Index (RSI)
- JUNS N/A
- LSB 40.24
- Support Level
- JUNS N/A
- LSB $0.92
- Resistance Level
- JUNS N/A
- LSB $1.01
- Average True Range (ATR)
- JUNS 0.00
- LSB 0.06
- MACD
- JUNS 0.00
- LSB 0.01
- Stochastic Oscillator
- JUNS 0.00
- LSB 52.38
About JUNS JUPITER NEUROSCIENCES INC
Jupiter Neurosciences Inc is a clinical-stage research and development pharmaceutical company located in Jupiter, Florida. The company has developed a resveratrol platform product that targets the treatment of neuro-inflammation. Its platform product, JOTROL, offers potential therapeutic benefit to the majority of central nervous system diseases such as Alzheimer's disease, ataxias, and metabolic disorders such as Lysosomal Storage Disorders and mitochondrial diseases.
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.